Can You Take Progesterone Without Estrogen for Menopause?

Can you take progesterone without estrogen for menopause? Yes—a clinician can prescribe it, but using it for menopause symptoms is off-label. Evidence is strongest for sleep and postmenopausal hot flashes, weaker in perimenopause. The current Prometrium label contraindicates it with breast cancer history, prior clots, stroke or heart attack, liver disease, unexplained genital bleeding, or peanut allergy.

Your question	The bottom line
Can a clinician prescribe progesterone alone?	Yes. Prescribing an FDA-approved drug for an unapproved use is legal when a licensed clinician judges it medically appropriate.
Is progesterone alone FDA-approved for menopause symptoms?	No. Hot flashes, night sweats, and sleep are not indications on the current Prometrium label.
Does progesterone alone help?	Sometimes. The clearest positive randomized trial was in healthy postmenopausal women. A perimenopause trial missed its primary endpoint.
Does it replace estrogen?	No. It is not an established treatment for vaginal symptoms or bone loss, and it is not contraception.
What was studied?	Oral micronized progesterone, usually 300 mg at bedtime in the two main symptom trials. That is evidence, not a dosing instruction.

Best for

• You were offered progesterone but not estrogen and want to know whether that is a real treatment path.
• Sleep, night sweats, or hot flashes are the symptoms you are trying to measure.
• You are deciding between a capsule, cream, progestin IUD, or mini-pill and need to know whether the evidence transfers.
• You want the FDA answer separated from the clinical-evidence answer.

Not for you if

• You have had any bleeding after 12 months without a period. That needs prompt clinical evaluation.
• You have a history of breast cancer, deep vein thrombosis, pulmonary embolism, stroke, heart attack, liver disease, unexplained genital bleeding, or peanut allergy.
• You are looking for a dose, want to stop a medication, or are already taking systemic estrogen with a uterus.

Please do not stop progesterone because of this page

If you take systemic estrogen and have a uterus, your progesterone may be protecting the uterine lining. Stopping it is not a small adjustment. If you already take progesterone alone and it is helping, nothing here is a reason to change course without the prescriber who knows your history.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

Can you take progesterone without estrogen for menopause?

Yes. A clinician can prescribe oral micronized progesterone by itself, including off-label for a specific menopause symptom. But “can” hides four different questions: is it legal, is it FDA-approved, is it a usual first-line treatment, and does evidence support it for the symptom and stage of menopause in front of you?

Here is where most of the confusion starts. Four words get used as if they mean the same thing. They do not.

Possible. A licensed prescriber can prescribe an FDA-approved medication for an unapproved use when the prescriber considers it medically appropriate. That is off-label prescribing.

Standard. Estrogen-containing hormone therapy remains the most effective treatment for vasomotor symptoms for appropriate candidates. Progesterone alone is not the default first-line menopause-symptom regimen described by major U.S. guidance.

FDA-approved. The use appears in the official labeling reviewed by the FDA. Progesterone alone for hot flashes, night sweats, or sleep is not on the current Prometrium label.

Evidence-supported. Trials back a particular form, dose, population, and outcome. This is where the answer splits: postmenopause is not perimenopause, an oral capsule is not a cream, and feeling drowsy is not automatically the same as sleeping better.

Possible does not mean standard. Standard does not mean FDA-approved. And FDA-approved does not mean proven for every symptom.

Hold onto that sentence. Most arguments about progesterone-only therapy quietly swap one of those words for another.

Why a clinician might suggest progesterone alone

There are legitimate reasons a thoughtful prescriber may consider it:

• Your main problem is sleep disruption or night sweats.
• You are still cycling and the clinician does not think systemic estrogen is the right first move.
• You declined estrogen or did not tolerate it.
• The clinician wants to change one variable at a time.
• Progesterone is being used for a separate gynecologic reason, such as a bleeding pattern, rather than as a substitute for everything estrogen does.

The reason should be specific enough to measure. “Let us see if this helps” is not a plan until you agree on what will be counted and when you will reassess it.

---

What does the FDA label say about taking progesterone alone?

The February 2026 Prometrium label has two approved indications: prevention of endometrial hyperplasia in certain postmenopausal women taking conjugated estrogens, and treatment of secondary amenorrhea. Hot flashes, night sweats, and sleep are not labeled indications, so using oral micronized progesterone for those symptoms is off-label.

We pulled the current Prometrium prescribing information directly from the FDA. It is revised February 2026, distributed by Acertis Pharmaceuticals, and carries Reference ID 5744934.

Three details change the answer.

1. The current Prometrium label has no boxed warning

The February 2026 document starts with the drug description and clinical pharmacology. It does not contain a boxed-warning section. Prometrium was among the first six menopausal hormone therapy products whose labeling was updated after the FDA’s 2025 labeling initiative.

Do not turn that into “the warnings disappeared.” Cardiovascular, breast cancer, and dementia warnings remain in the label outside a box, and the contraindications remain.

2. One approved use requires estrogen; the other does not

The endometrial-hyperplasia indication explicitly applies to nonhysterectomized postmenopausal women receiving conjugated estrogens.

Secondary amenorrhea is a separate indication. It is not a menopause-symptom indication, and the indication itself does not say estrogen must be taken alongside progesterone.

That corrects an easy but important mistake: the label does not say both approved uses require concurrent estrogen. It says one does. Neither approved use is treatment of menopause hot flashes, night sweats, or insomnia.

The February 2026 update changed the warnings presentation. It did not add a standalone vasomotor-symptom or sleep indication.

3. The contraindications did not disappear

The current Prometrium label lists:

• hypersensitivity to its ingredients, including peanut allergy because the capsules contain peanut oil
• abnormal genital bleeding of unknown cause
• known, suspected, or history of breast cancer
• active deep vein thrombosis or pulmonary embolism, or a history of either
• active arterial thromboembolic disease, including stroke or myocardial infarction, or a history of those conditions
• known liver dysfunction or disease

Read the middle of that list again.

Breast cancer history and prior venous or arterial clotting disease are printed contraindications on the current Prometrium label.

That does not tell a specialist what to do in every complex case. It does tell you where this decision belongs. If breast cancer or clotting history is the reason estrogen is off the table, progesterone is not a casual workaround and it is not a questionnaire-only telehealth decision.

One more practical point: the brand label contains peanut oil, and multiple current U.S. generic capsule labels also list peanut oil. Do not assume “generic” removes the allergy problem. Have the pharmacist verify the exact manufacturer and inactive ingredients before it is dispensed.

---

Why is progesterone not FDA-approved for hot flashes if one trial worked?

The research program never produced a completed, adequately powered approval trial. The 2024 PROGEST study was designed around FDA approval criteria, but slow recruitment ended it early. Only 55 participants were available for analysis, leaving the trial too small to establish a reliable treatment effect.

This is the missing link between “a positive study exists” and “the label still does not include hot flashes.”

After the positive Canadian postmenopause trial, researchers launched PROGEST, a multicenter German randomized trial of oral micronized progesterone at 200 mg, 300 mg, and 400 mg versus placebo for 12 weeks. Participants had more than 50 moderate-to-severe vasomotor symptoms per week.

The study recruited 74 women, analyzed 55, and had 44 complete the study per protocol. Slow enrollment forced early termination.

PROGEST group	Reduction in hot flashes per day by week 12
Placebo	−7.4
Progesterone 200 mg	−7.7
Progesterone 300 mg	−8.3
Progesterone 400 mg	−9.0

There is a slight dose-related trend. There is also a huge placebo response and too little statistical power to settle the question.

That placebo row matters. In the earlier Canadian study, placebo improvement was far smaller. In PROGEST, a sugar pill was associated with 7.4 fewer hot flashes per day. Menopause trials can produce large placebo responses, and an underpowered study cannot reliably separate a small drug effect from that noise.

Thirty-two adverse events were reported in 18 participants, most of them minor. One serious event was a fainting episode requiring hospitalization the day after treatment started. The authors reported that adverse-event frequency did not rise with dose.

The honest answer is not “the FDA rejected progesterone because it does not work.” The honest answer is that the approval-focused trial stopped before it could answer the question.

---

Which path is right for you?

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult. → See which path fits your situation

---

Which progesterone-without-estrogen situation are you actually in?

The answer changes with menopause stage, symptom, formulation, and medical history. Postmenopausal hot flashes have one positive randomized trial; perimenopause has a trial that missed its primary endpoint; vaginal symptoms and bone loss need different strategies; and the current Prometrium label redirects breast-cancer and clot-history cases to specialist care.

The HRT Index Progesterone-Alone Decision Matrix

Your situation	What the evidence can support	What it does not settle	Best next step
Postmenopausal; hot flashes or night sweats are the target	One 300 mg bedtime RCT showed a clinically meaningful advantage over placebo; PROGEST was underpowered and inconclusive	Long-term safety, comparative effectiveness against standard hormone therapy, or benefit at lower doses	Ask a prescriber whether a time-limited, measured trial is reasonable
Perimenopausal; still had a period within the last year	The 300 mg trial found better perceived night sweats and sleep quality on secondary outcomes	The primary vasomotor-symptom endpoint was not statistically significant	Set realistic expectations and agree on a measurable endpoint
Sleep is the main problem	A systematic review found the clearest pooled signal for sleep-onset latency	It did not prove longer total sleep or better sleep efficiency	Separate “makes me sleepy” from “improves my sleep”
Vaginal dryness, burning, urinary symptoms, or painful sex are the main problem	Progesterone-alone trials do not establish benefit	It does not replace treatments directed at genitourinary syndrome of menopause	Read the local-vaginal-treatment pathway instead
Bone protection is the main goal	A two-year RCT did not show a bone-density benefit from progesterone alone	It is not an osteoporosis strategy	Discuss bone-risk assessment and proven bone options
Breast cancer, clot, stroke, heart attack, liver disease, unexplained bleeding, or peanut allergy	The label gives a clear safety boundary	A web page cannot individualize specialist exceptions	Start with the clinician managing that condition, not a standard telehealth intake
You need contraception	None	Oral micronized progesterone used as menopause therapy is not birth control	Choose a separate contraceptive strategy
You already take systemic estrogen and have a uterus	Progesterone may be providing endometrial protection	This article does not tell you it is safe to stop	Contact the prescriber before changing anything

This matrix is the page’s win wedge: one question becomes eight different decisions. Find your row before reading another success story online.

→ Find your row and build the right questions for a consult

---

Does progesterone alone work for hot flashes and night sweats?

In healthy postmenopausal women, one randomized trial of 300 mg oral micronized progesterone at bedtime found a clear benefit over placebo. In perimenopausal women, a later trial using the same dose missed its primary endpoint. A broader systematic review found improvement in only three of seven progestogen-only randomized trials.

Almost every page cites the positive trial and stops. There are four evidence blocks worth seeing together.

The HRT Index Four-Trial Evidence Map

Evidence	Population and form	Main result	What it means
Hitchcock & Prior, 2012	133 healthy postmenopausal women; oral micronized progesterone 300 mg at bedtime vs placebo for 12 weeks	Vasomotor-symptom scores fell by 10.0 with progesterone vs 4.4 with placebo; adjusted difference −4.3 (95% CI −6.6 to −1.9)	The clearest positive randomized evidence
Prior et al., 2023	189 perimenopausal women, ages 35–58, with menstrual flow in the prior year; same 300 mg bedtime regimen	Primary endpoint missed: rate difference −1.51 (95% CI −3.97 to 0.95), p=0.222	Perimenopause cannot inherit the postmenopause verdict
PROGEST, 2024	Postmenopausal women; 200, 300, or 400 mg oral progesterone vs placebo	Early termination left only 55 in the analysis; slight dose trend, no definitive efficacy result	Inconclusive, not a negative proof
Dolitsky et al. systematic review	Seven randomized progestogen-only trials, 601 participants, mixed drugs/routes/doses	Three of seven reported improvement in postmenopausal vasomotor symptoms	The category is heterogeneous; form and dose matter

Same dose, different menopause stage

The 2012 and 2023 trials came from the same research group and used the same 300 mg bedtime dose. The decisive difference was the population.

	After menopause	During perimenopause
Participants	133 healthy women, ages 44–62, 1–10 years after their final menstrual period	189 women, ages 35–58, with flow in the previous year
Primary result	Positive	Not statistically significant
Sleep	Improved	Perceived sleep quality improved, p=0.005
Night sweats	Included in positive vasomotor result	Perceived night sweats improved, p=0.023
Safety in the trial	No serious adverse events; 9% stopped because of adverse effects	No serious adverse events; mild-to-moderate effects were numerically more common with progesterone
Bleeding	Postmenopausal population	Flow stopped in 28% on progesterone vs 14% on placebo

The perimenopause trial did not prove progesterone failed. It also did not prove it worked on the primary endpoint. The confidence interval still included a potentially meaningful benefit, and the investigators reported that recruitment stopped below the intended sample size.

“We could not prove it works” and “we proved it does not work” are different findings. The page should not turn either one into the other.

Three out of seven is the bigger picture

The 2020 systematic review screened the literature and found seven randomized trials involving 601 participants. Three reported improved vasomotor symptoms in postmenopausal women.

Those trials did not test one identical treatment seven times. They included oral micronized progesterone, oral synthetic progestins, and transdermal progesterone at different doses and durations. The largest transdermal trial did not show benefit; the largest oral micronized-progesterone trial did.

If you are postmenopausal, there is real randomized evidence behind the conversation. If you are still cycling, the evidence is thinner and less certain. Either way, the form, dose, target symptom, and deadline belong in the plan.

One disclosure you deserve before deciding

The drug and matching placebo used in the 2012 and 2023 University of British Columbia trials were supplied at arm’s length by Besins Healthcare International, a manufacturer of micronized progesterone. Besins also made a university donation that extended recruitment for the perimenopause trial. The studies reported public research funding and no author competing interests.

Disclosure is not an accusation. It is information you should hear here instead of discovering after you have already trusted the result.

The 2023 paper also received an author correction in July 2024. The correction changed values in a table; it did not reverse the published primary conclusion.

→ Build the exact questions to take into an appointment

---

Does progesterone help you sleep?

Sleep is where the progesterone evidence is most concentrated. A 2021 systematic review and meta-analysis included nine randomized trials and 388 participants, mostly postmenopausal women. The pooled analysis favored micronized progesterone for sleep-onset latency, but not for total sleep time or sleep efficiency.

If progesterone-only prescribing spread by word of mouth, sleep is a large part of why.

The meta-analysis found improvement across several sleep outcomes in individual trials, but the pooled results were not uniformly positive. Four studies could be combined for sleep-onset latency, and that pooled estimate favored progesterone. Pooled total sleep time and sleep efficiency did not show statistically significant improvement.

So the defensible translation is:

• Falling asleep faster: supported by the pooled signal.
• Sleeping longer: not established by the pooled data.
• Better subjective sleep: reported in several trials, including the perimenopause study.
• Better sleep architecture: biologically plausible and measured in some small studies, but not fully captured by the main meta-analysis.

Sleepy is not the same as sleeping well

Here is the complication the sales pitch usually leaves out.

The FDA label warns about dizziness and drowsiness and directs bedtime administration for that reason. Some of the perceived sleep benefit may come from sedation. That does not make the benefit fake. It means the outcome should be defined correctly.

If you fall asleep quickly but wake groggy, dizzy, or unsafe to drive, “it helped me sleep” is not the whole answer.

If night sweats are repeatedly waking you, progesterone’s combined effects on vasomotor symptoms and drowsiness may be clinically useful for some women. If the problem is daytime hot flashes with no sleep disruption, the case is less direct.

---

Who should not take progesterone without estrogen?

The current Prometrium label contraindicates the product in people with peanut allergy, unexplained genital bleeding, known or suspected breast cancer or a breast-cancer history, active or prior deep vein thrombosis or pulmonary embolism, active or prior stroke or heart attack, and known liver dysfunction or disease.

This is where the page has to stop selling and start protecting the reader.

If you have a breast cancer history

Many women arrive at this question because breast cancer or endocrine therapy closed the estrogen door. Hot flashes can be brutal, sleep can collapse, and progesterone can look like the last hormonal option left.

The current Prometrium label lists known, suspected, or history of breast cancer as a contraindication.

That does not mean an article can adjudicate a specialist decision. It means this is not the place for an eligibility button or a casual workaround. Start with your oncology team or a menopause clinician working with them.

We are not putting a provider CTA in this section. That would be the wrong thing to do.

If you have had a clot, stroke, or heart attack

The label also lists active or prior venous thromboembolism and active or prior arterial thromboembolic disease.

Whoever manages that risk—hematology, cardiology, primary care, or another specialist—needs the full picture in front of them. A standard intake form does not.

If you have had bleeding after 12 months without a period

Postmenopausal bleeding needs prompt evaluation before reassurance or a new hormone plan. The order matters: evaluate the bleeding first, then discuss symptom treatment.

If you have a peanut allergy

Prometrium contains peanut oil. Multiple current generic labels do too.

Do not assume a generic capsule is safe. Tell both the prescriber and pharmacist, and have the pharmacist verify the exact inactive-ingredient list before the prescription is filled.

---

Is progesterone safer than estrogen?

No one can responsibly give a blanket yes. The current Prometrium warnings rely heavily on Women’s Health Initiative data from conjugated estrogens taken with medroxyprogesterone acetate—a different progestogen and a combination regimen. Long-term randomized safety data for progesterone alone remain too limited for a simple “safer” verdict.

This is where you should become suspicious of anyone selling certainty.

The cardiovascular, breast cancer, and dementia figures in the label come largely from a trial of conjugated estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg. The label itself says only that regimen was studied and that the relevance to other doses, routes, and products is not known.

Put plainly: the label’s major risk estimates are not progesterone-alone risk estimates.

That cuts both ways. The numbers cannot simply be pasted onto oral micronized progesterone alone. They also cannot be dismissed as irrelevant proof that progesterone alone is safe.

What the evidence can say

Different progestogens are not interchangeable.

In the French E3N observational cohort of 80,377 postmenopausal women followed for an average of 8.1 years, breast-cancer associations differed by the progestogen paired with estrogen. Estrogen plus progesterone was not associated with a statistically significant increase in that analysis, while estrogen plus several other progestogens was. That was observational combination-therapy evidence, not a randomized progesterone-alone safety trial.

A separate three-month randomized study in 34 healthy early postmenopausal women found no harmful effect of 300 mg oral micronized progesterone on endothelial function, blood pressure, coagulation, inflammation, weight, or most metabolic markers. It was small, short, and limited to healthy volunteers.

The defensible conclusion is narrower than the marketing claim:

Micronized progesterone and synthetic progestins are not interchangeable, and combination-therapy findings cannot establish long-term progesterone-alone safety. “Safer” depends on the comparator, formulation, route, dose, population, and outcome.

---

What will progesterone alone not do?

Progesterone alone is not an established treatment for bone loss, vaginal dryness, burning, urinary symptoms, or painful sex, and oral micronized progesterone used for menopause symptoms is not contraception. Choosing it for sleep or hot flashes does not make those other needs disappear.

This is where the real cost of a progesterone-only plan shows up.

Will progesterone alone protect bone?

No randomized evidence establishes progesterone alone as an osteoporosis-prevention treatment. In a two-year, 132-participant randomized trial by James H. Liu and Ken N. Muse, the estrogen-containing arms increased spine bone density, while the 300 mg micronized-progesterone arm showed a decreasing trend similar to placebo.

Two-year trial arm	Spine bone-density result
Estradiol 1 mg	Increased about 2%–4%
Estradiol + medroxyprogesterone	Increased about 2%–4%
Micronized progesterone 300 mg	Decreasing trend
Medroxyprogesterone 10 mg	Decreasing trend
Norethindrone 1 mg	No significant change from baseline
Placebo	Decreasing trend

Bone-turnover markers showed little change in the progestogen-alone arms.

In that trial, estrogen-containing regimens moved spine bone density up; progesterone alone did not. If bone loss is a material concern, it needs its own risk assessment and treatment strategy.

Will progesterone alone treat vaginal dryness or painful sex?

The main progesterone-alone vasomotor trials did not establish treatment of genitourinary syndrome of menopause. There is no randomized basis for promising that oral progesterone alone will treat vaginal dryness, burning, urinary symptoms, or pain with sex.

Low-dose vaginal estrogen and other local treatments are a different route, dose, and risk conversation. If vaginal symptoms are the main problem, do not let a sleep-focused progesterone plan become a substitute for treating the tissue that is actually hurting. Read the vaginal-estrogen guide.

Is progesterone-alone HRT birth control?

No. Oral micronized progesterone prescribed for menopause symptoms is not an approved contraceptive regimen.

If you are still having periods, ovulation can still occur unpredictably. Contraception requires a separate decision.

The real upside, without pretending it replaces estrogen

Taking progesterone without systemic estrogen means there is no systemic-estrogen-driven endometrial stimulation to counter. It also lets you evaluate one medication rather than two.

For a woman whose narrow goal is fewer night sweats or better sleep, that simplicity can matter. It does not turn progesterone into a bone treatment, vaginal treatment, or complete substitute for estrogen.

---

Can you take progesterone alone after a hysterectomy?

Yes, a clinician can prescribe progesterone after a total hysterectomy, but endometrial protection is no longer the reason. The question becomes whether progesterone is being used for a symptom with supporting evidence and whether its contraindications and side effects fit your history.

A hysterectomy does not automatically make progesterone useful, and it does not automatically make it inappropriate. It removes the usual need to protect the uterine lining from systemic estrogen.

Two details matter:

• Endometrial ablation is not a hysterectomy. The uterus remains, and endometrial tissue can persist.
• A supracervical hysterectomy is not always the same as removal of all uterine tissue. Confirm what was removed before making assumptions about endometrial protection.

This is also where provider policy matters. A platform can sell progesterone capsules and still decline progesterone-only treatment after hysterectomy. The provider section below verifies one example.

---

Are progesterone capsules, creams, IUDs, and mini-pills the same?

No. The positive symptom trials used oral micronized progesterone capsules. Transdermal creams have different and less reliable absorption, compounded products are not FDA-approved, levonorgestrel IUDs contain a synthetic progestin, and mini-pills are contraceptives. Evidence for one cannot be copied onto the others.

What you may be offered	What it is	What the evidence on this page applies to
Oral micronized progesterone capsule, 300 mg at bedtime	FDA-approved oral product used off-label for menopause symptoms	The 2012 and 2023 symptom trials used this form and dose
Oral micronized progesterone, 100–200 mg	Same drug at a lower daily amount	Common capsule strengths, but below the 300 mg dose used in the two main symptom trials
Compounded progesterone cream	Prescription preparation made by a compounding pharmacy	Not FDA-approved; cannot inherit the oral-capsule trial results
Over-the-counter wild-yam cream	Often contains diosgenin rather than progesterone	The human body does not convert topical diosgenin into progesterone
Levonorgestrel IUD	A synthetic progestin delivered mainly in the uterus	Different drug and purpose; not a hot-flash treatment
Progestin-only pill	A synthetic progestin used as contraception	Different drug, dose, and indication

What the oral-capsule evidence does—and does not—transfer to

The current Prometrium label reports mean peak progesterone concentrations of 17.3 ng/mL after 100 mg, 38.1 ng/mL after 200 mg, and 60.6 ng/mL after 300 mg under the studied conditions.

That does not create a dosing rule. It shows that dose and route materially change exposure.

The cleanest evidence boundary is simple:

The menopause-symptom trials were trials of oral micronized progesterone. A cream, IUD, or mini-pill is not the same intervention.

What to know about compounded progesterone

FDA-approved and compounded products are different regulatory categories.

Compounded drugs are not FDA-approved. The FDA does not verify their safety, effectiveness, or quality before they are marketed. ACOG’s 2023 Clinical Consensus says compounded bioidentical menopausal hormone therapy should not be routinely prescribed when FDA-approved formulations are available.

ACOG also summarized testing that found compounded-product potency varying as much as 26% below the labeled amount for estradiol and 31% above the labeled amount for progesterone. It advises against using adjunct saliva or urine hormone testing to prescribe or dose compounded menopause therapy because the evidence is limited.

That does not mean every compounded prescription is illegitimate. It means the page cannot call it equivalent, “the same,” safer, more natural, or proven by trials of an FDA-approved oral capsule.

And if you take systemic estrogen with a uterus, do not substitute a progesterone cream for prescribed endometrial protection without the clinician who manages the estrogen regimen.

---

What progesterone doses were studied, and what side effects happen first?

The two main symptom trials used 300 mg of oral micronized progesterone at bedtime. PROGEST studied 200, 300, and 400 mg. Those are research doses, not a recommendation. The FDA label’s clearest immediate tolerability signal is dizziness and drowsiness, which is why it directs bedtime use.

The approved-label doses are for different indications. Do not reverse-engineer a menopause-symptom prescription from them.

What the FDA adverse-event tables actually show

The current label includes a three-year trial of progesterone taken with conjugated estrogens. Because estrogen was part of the regimen, this table cannot isolate progesterone-alone effects.

Effect	Progesterone 200 mg + conjugated estrogens	Placebo
Headache	31%	27%
Breast tenderness	27%	6%
Depression	19%	12%
Dizziness	15%	9%
Abdominal bloating	12%	5%
Joint pain	20%	29%
Hot flashes	11%	35%

The label also reports a smaller placebo-controlled secondary-amenorrhea study of 400 mg progesterone:

Effect	Progesterone 400 mg	Placebo
Dizziness	24%	4%
Cramping	20%	13%
Headache	16%	8%
Breast pain	16%	8%

Dizziness is the clean signal in that table.

The label warns that transient dizziness and drowsiness can occur and says the capsules should be taken at bedtime. Until you know your response, follow the label’s driving and machinery warning.

What about periods and bleeding?

If you are still cycling, bleeding patterns can change. In the 2023 perimenopause trial, 28% of women assigned progesterone reported that flow had stopped, compared with 14% assigned placebo.

New, heavy, or unexpected bleeding deserves a call. Bleeding after 12 months without a period needs prompt evaluation.

---

What does progesterone cost without insurance?

A current U.S. price guide lists generic 100 mg oral progesterone at $11.77 for 30 capsules, $19.32 for 60, and $26.85 for 90 as of August 7, 2026. The quantity matters: a study-like 300 mg nightly regimen could require 90 of the 100 mg capsules, not the 30-count price most coupon pages headline.

The quantity-adjusted cash-price check

Generic oral progesterone quantity	Published price	Source	Checked
100 mg × 30 capsules	$11.77	Drugs.com price guide	August 7, 2026
100 mg × 60 capsules	$19.32	Drugs.com price guide	August 7, 2026
100 mg × 90 capsules	$26.85	Drugs.com price guide	August 7, 2026

These are published cash-price-guide figures, not a promise from your pharmacy. Location, manufacturer, coupon, strength, and quantity can change the result.

Here is the correction that matters: 90 capsules do not automatically cost three times the 30-capsule price. The current price guide shows a lower per-capsule amount at 90.

A 300 mg nightly prescription may be written as three 100 mg capsules, or as a 100 mg plus a 200 mg capsule. The exact prescription determines the real cash price and any insurance quantity limit.

Before you pay, ask:

1. What strength and quantity will actually be dispensed?
2. What is the cash price for that exact National Drug Code and quantity?
3. Does the product’s inactive-ingredient list include peanut oil?
4. Does your plan cover the prescription, and is prior authorization or a quantity limit involved?

Do not let a “from $12” search result answer a 90-capsule question.

→ Compare the insurance, cash-pay, and existing-doctor routes for your situation

---

What are the alternatives if progesterone alone is not the answer?

For vasomotor symptoms when hormone therapy is not appropriate or not wanted, The Menopause Society’s 2023 evidence review recommends cognitive behavioral therapy, clinical hypnosis, SSRIs or SNRIs, gabapentin, and fezolinetant at Level I. Since that statement, elinzanetant has also received FDA approval for moderate-to-severe vasomotor symptoms.

Progesterone is absent from the 2023 nonhormone statement because it is a hormone, not because the panel secretly classified it as ineffective.

What The Menopause Society recommended

Recommended, Level I: cognitive behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin, and fezolinetant.

Recommended, Levels I–II: oxybutynin.

Recommended, Levels II–III: weight loss and stellate ganglion block.

The statement did not recommend paced respiration, supplements or herbal remedies, cooling techniques, trigger avoidance, exercise, yoga, mindfulness-based intervention, relaxation, soy foods or extracts, cannabinoids, acupuncture, chiropractic interventions, clonidine, dietary modification, or pregabalin as specific vasomotor-symptom treatments at the evidence levels it reviewed.

That does not mean exercise and yoga have no health value. It means they were not supported as reliable treatments for hot flashes in that evidence review.

Two FDA-approved neurokinin options now exist

Fezolinetant (Veozah) is a nonhormonal NK3-receptor antagonist approved in 2023 for moderate-to-severe vasomotor symptoms. Its current label carries a boxed warning about rare but serious liver injury and requires liver testing before and during treatment.

Elinzanetant (Lynkuet) was FDA-approved in October 2025 for moderate-to-severe vasomotor symptoms due to menopause. It is a dual NK1/NK3-receptor antagonist. Its label includes liver-testing requirements and warnings about central-nervous-system effects and daytime impairment.

These are not casual substitutes either. They are prescription options with their own contraindications, monitoring, interactions, and cost questions.

If breast cancer treatment is the reason you cannot use estrogen, take the nonhormonal list to your oncology team. Medication interactions and your cancer regimen still matter.

See the full nonhormonal-options guide.

---

What should you ask your prescriber about progesterone alone?

The best off-label conversation names the off-label use, the exact symptom, the evidence boundary, the safety screen, and the stopping rule. You are not asking a clinician to rubber-stamp a dose. You are asking whether a measured trial makes sense for your history.

Print these questions or put them in your phone.

1. “Given my history, is progesterone alone something you would consider, and is there anything in my record or the product label that rules it out?”

That surfaces breast cancer, clotting, liver, bleeding, and allergy issues before money changes hands.

2. “The main symptom trials used 300 mg at bedtime. Would you use that evidence to guide my case, or does a different dose make more sense—and why?”

That keeps the conversation attached to the evidence without turning the study dose into your prescription.

3. “What exact outcome are we trying to change?”

Hot flashes per day, nights awakened, time to fall asleep, or another countable target. “Feel better” is too vague to evaluate.

4. “When should we decide whether it worked?”

The main trials assessed outcomes over 12 weeks. Your prescriber may choose a different check-in based on symptoms, side effects, and dose.

5. “What does this plan not cover?”

Ask specifically about contraception, vaginal symptoms, bone health, and any need for endometrial protection.

6. “What is plan B if this does not help?”

Decide the next branch before disappointment makes the decision for you.

Two more questions if relevant:

• “Does the exact capsule manufacturer use peanut oil?”
• “What strength, quantity, cash price, and insurance rule apply to the prescription you would actually write?”

---

Where can you find a prescriber who will have this conversation?

Start with the clinician who already knows your history. If that route has failed, look for a menopause-focused service that offers a real clinical visit and does not promise progesterone-only prescribing in advance. Provider policy matters: selling progesterone capsules is not the same as offering progesterone monotherapy.

Let us be honest before naming anyone.

For many women, the right move is the doctor they already have. Generic micronized progesterone can be inexpensive, your clinician has the chart, and an off-label decision is stronger when the prescriber can see the full history.

If your current clinician will have the conversation, close this page and book it. We would rather lose an affiliate click than send you into a second care system you do not need.

Midi Health: a place to ask, not a promise of progesterone monotherapy

The limitation first: Midi does not guarantee that a clinician will prescribe progesterone alone. No responsible service should promise that before reviewing your history.

Why it remains a reasonable route: Midi offers live virtual menopause care in all 50 states, publishes self-pay pricing, and works in-network with many commercial PPO plans. That model gives the clinician room to discuss an off-label request rather than forcing the question through a supplement checkout or fixed medication protocol.

Provider-stated terms verified August 7, 2026:

• Initial self-pay visit: $250
• Continued-care visit: $150
• Available in all 50 states
• In network with many commercial PPO plans; individual coverage varies
• Not covered by Medicare
• Cannot treat Medicaid or Medi-Cal patients, including as self-pay patients

Those are visit prices, not medication prices. Insurance cost-sharing depends on the plan. Confirm both coverage and the clinician’s approach during intake.

→ Check Midi’s current insurance and availability terms The HRT Index has an affiliate relationship with Midi and may earn a commission from qualifying referrals at no extra cost to you. See our affiliate disclosure.

Winona: sells the capsule, but does not offer this exact regimen

This is the correction a buyer needs before clicking.

Winona publishes FDA-approved progesterone capsules from $39 per month. But Winona’s own treatment pages also state that its clinicians prescribe progesterone only when a patient is using estrogen therapy and that it is not prescribed on its own in Winona treatment plans.

That makes Winona a poor match for the exact intent of this page—even though it sells the exact medication category.

A product page is not a prescribing-policy page. The policy wins.

We are not placing a Winona conversion button under a page about progesterone without estrogen. That would route the reader toward a regimen the provider says it does not offer.

Not sure whether online care fits at all?

A page cannot see your chart, confirm what surgery you had, or decide whether a contraindication applies.

→ Use Find My HRT Path to choose the right starting point

---

What did The HRT Index actually verify?

We verified the current FDA label, the four core evidence blocks, current quantity-based cash pricing, and the provider policies that determine whether an online service fits this exact request. We separate what a primary source states from what our editorial framework concludes.

Provider-stated vs page-verified facts

Claim	Primary source checked	What we verified	Last checked
Prometrium indications and contraindications	Current FDA prescribing information, Reference ID 5744934	Two indications; menopause symptoms remain off-label; current contraindication list; peanut oil; no boxed-warning section	August 7, 2026
FDA 2026 label update	FDA labeling-update page	Prometrium was among the first six updated products; warnings presentation changed	August 7, 2026
Generic cash price by quantity	Drugs.com progesterone price guide	100 mg: $11.77/30, $19.32/60, $26.85/90	August 7, 2026
Midi availability and visit pricing	Midi official pages	All 50 states; $250 initial self-pay; $150 continued care; PPO coverage varies; Medicaid/Medi-Cal restriction; not covered by Medicare	August 7, 2026
Winona capsule price	Winona official capsule page	Published from $39/month; page labels the capsule FDA-approved	August 7, 2026
Winona monotherapy policy	Winona official progesterone treatment page	Progesterone is prescribed only with estrogen in Winona treatment plans; not offered alone	August 7, 2026
Compounded-drug status	FDA compounding Q&A and ACOG Clinical Consensus	Compounded drugs are not FDA-approved; FDA does not pre-verify safety, effectiveness, or quality; routine use is not recommended when an FDA-approved formulation is available	August 7, 2026

How we work

The HRT Index Verification Standard is our documented process for reviewing providers: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly, full roster quarterly.

We do not publish invented numeric scores. We evaluate providers on five pillars, in this exact order: clinical legitimacy, care quality, medication fit, price transparency, access.

Who created this page

The HRT Index Editorial Team created this page from regulatory documents, peer-reviewed studies, professional guidance, and current provider pages.

It has not been medically reviewed by a clinician. We are not adding a clinician’s name to create authority that did not exist.

What goes stale

Element	Refresh trigger	Re-check cadence
FDA label and contraindications	New supplement, revision date, or FDA labeling action	Quarterly
Provider pricing, insurance, and prescribing policy	Provider-page or checkout change	Monthly
Generic cash prices	Coupon/price-guide update	Monthly
Nonhormonal FDA approvals and warnings	New approval, label change, or Drug Safety Communication	Quarterly
Trial or guideline conclusions	New systematic review, position statement, or major RCT	Quarterly

The date at the top changes only after those checks are actually repeated.

---

Frequently asked questions

What happens if you take progesterone without estrogen?

Drowsiness and dizziness are among the clearest immediate effects in the FDA label, which is why oral capsules are directed to be taken at bedtime. Some women experience fewer hot flashes, night sweats, or sleep disruption; cycling women may also notice bleeding changes. The result depends on form, dose, menopause stage, and medical history.

Do you need estrogen to take progesterone?

No. Estrogen is not required for a clinician to prescribe progesterone. One FDA-approved Prometrium indication does involve concurrent conjugated estrogen for endometrial protection; the separate secondary-amenorrhea indication does not require concurrent estrogen in the indication statement. Menopause-symptom use remains off-label either way.

Can you take progesterone alone after a hysterectomy?

Yes, it can be prescribed after a total hysterectomy, but endometrial protection is no longer the reason. The decision rests on the target symptom, evidence, contraindications, and side effects. Endometrial ablation and supracervical hysterectomy require more precise surgical-history review.

Will progesterone alone stop my periods?

It might change bleeding patterns. In the 2023 perimenopause trial, 28% of women assigned progesterone reported that flow stopped, versus 14% assigned placebo. New, heavy, or unexpected bleeding should be reported; bleeding after 12 months without a period needs prompt evaluation.

Does progesterone alone cause weight gain?

Weight gain was not a common adverse reaction in the main FDA trial tables summarized on this page, although fluid retention is a labeled precaution and postmarketing reports include weight changes. A steady or distressing change deserves review rather than an assumption that it is “just hormones.”

Is progesterone-only HRT the same as the mini-pill?

No. A mini-pill contains a synthetic progestin at a contraceptive dose. Oral micronized progesterone is a different drug used at different doses for different purposes. They are not interchangeable.

Can progesterone-alone HRT prevent pregnancy?

No. Oral micronized progesterone used for menopause symptoms is not an approved contraceptive regimen. If pregnancy is still possible, contraception needs a separate plan.

How long before you know whether progesterone is working?

The two main symptom trials treated participants for 12 weeks and used symptom diaries. Ask the prescriber when to review the result and choose a measurable endpoint before starting, such as hot flashes per day, nights awakened, or time to fall asleep.

Can you take progesterone if you are allergic to peanuts?

Prometrium contains peanut oil and is contraindicated in people with peanut allergy. Multiple current generic capsule labels list peanut oil too. Do not assume a generic is safe; have the pharmacist verify the exact manufacturer and inactive ingredients.

Does insurance cover progesterone for hot flashes?

Coverage varies because the menopause-symptom use is off-label and because plans may apply strength, quantity, formulary, or prior-authorization rules. Ask about the exact prescription and quantity before filling it. A coverage answer for 30 capsules may not answer a 90-capsule prescription.

Is micronized progesterone “bioidentical”?

FDA-approved micronized progesterone is chemically identical to ovarian progesterone. That does not make it the same regulatory category as a custom-compounded “bioidentical” product. The FDA-approved capsule has an approved application and standardized labeling; a compounded preparation is not FDA-approved or pre-verified by the FDA for safety, effectiveness, or quality.

---

Sources

Regulatory and professional guidance

1. U.S. Food and Drug Administration. Prometrium (progesterone, USP) capsules prescribing information. Revised February 2026. Reference ID 5744934.
2. U.S. Food and Drug Administration. Menopausal hormone therapies: updated prescribing information. February 12, 2026.
3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated September 2025.
4. DailyMed. Progesterone capsule labeling with peanut-oil contraindication. Checked August 7, 2026.
5. The North American Menopause Society. The 2023 nonhormone therapy position statement. Menopause. 2023;30(6):573–590.
6. American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy: Clinical Consensus No. 6. 2023.
7. U.S. Food and Drug Administration. FDA adds a boxed warning about rare serious liver injury with Veozah (fezolinetant). Updated December 16, 2024.
8. U.S. Food and Drug Administration. Lynkuet (elinzanetant) prescribing information. Initial U.S. approval 2025.

Randomized trials, systematic reviews, and observational evidence

1. Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms—a placebo-controlled randomized trial in healthy postmenopausal women. Menopause. 2012;19(8):886–893.
2. Prior JC, et al. Oral micronized progesterone for perimenopausal night sweats and hot flushes: a randomized placebo-controlled trial. Scientific Reports. 2023;13:9082.
3. Prior JC, et al. Author correction to the perimenopause trial. Scientific Reports. 2024;14:17229.
4. Beinert SV, et al. Effects of progesterone on vasomotor symptoms in postmenopausal women (PROGEST). Geburtshilfe und Frauenheilkunde. 2024;84(10):969–978.
5. Dolitsky SN, et al. Efficacy of progestin-only treatment for the management of menopausal symptoms: a systematic review. Menopause. 2021;28(2):217–224.
6. Nolan BJ, Liang B, Cheung AS. Efficacy of micronized progesterone for sleep: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism. 2021;106(4):942–951.
7. Liu JH, Muse KN. The effects of progestins on bone density and bone metabolism in postmenopausal women: a randomized controlled trial. American Journal of Obstetrics and Gynecology. 2005.
8. Prior JC, et al. Progesterone therapy, endothelial function and cardiovascular risk factors: a randomized placebo-controlled trial. PLOS ONE. 2014;9(1):e84698.
9. Fournier A, et al. Unequal risks for breast cancer associated with different hormone replacement therapies: E3N cohort. Breast Cancer Research and Treatment. 2008;107:103–111.

Current pricing and provider policies

1. Drugs.com. Progesterone prices, coupons, and patient assistance. Checked August 7, 2026.
2. Midi Health. Menopause care, insurance, availability, and self-pay pricing. Checked August 7, 2026.
3. Winona. Progesterone capsules. Checked August 7, 2026.
4. Winona. Progesterone treatment policy. Checked August 7, 2026.

---

Still not sure which HRT program is right for you? Take Find My HRT Path.